VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2011

1
Aarkstore.in VEGF Inhibition
Therapy-Indicating and Prognostic Biomarkers, 2011
2
Summary

• Vascular Endothelial Growth Factor (VEGF), which
  plays an important role in angiogenesis, has been
  extensively studied and over-expression is seen
  in many cancers. Today, VEGF is targeted using
  antibodies and tyrosine kinase inhibitors, and
  antiangiogenic therapy is a standard treatment
  for many cancers, including colorectal and
  non-small cell lung cancer. While VEGF
  inhibitors such as bevacizumab (Avastin) provide
  valuable treatment options, these benefits are
  not seen in all patients and cancer types. Today,
  there is an urgent need for predictive biomarkers
  to enable those patients most likely to benefit
  from VEGF inhibition, to be identified. This
  report (see brochure) provides a review of
  findings to date on biomarkers associated with
  the use bevacizumab (Avastin) both
  therapy-indicating and prognostic.The
  identification of therapy-indicating and
  prognostic biomarkers relating to antiangiogenic
  therapy is in its early stages, however important
  advances have been made. This report identifies
  the latest findings on ten different cancers and
  includes an evaluation of candidate biomarkers as
  a basis for interpreting patient outcomes
  according to RECIST criteria, and evaluates
  existing bevacizumab-containing treatments and
  drug combinations.

3
Table of Contents

• Chapter 1 Background (p.18)1.1 VEGF
  Inhibition1.2 Bevacizumab1.3 Biomarkers1.4
  This ReportChapter 2 Colorectal Cancer
  Candidate Biomarkers identified in Patients
  receiving Bevacizumab-containing Therapies (p.
  22)Summary2.1 Introduction2.2
  Glycoprotein2.3 Protein2.4 Protein2.5
  Cells2.6 Genetic2.7 Physical 2.8 Genetic2.9
  Protein2.10 Proteins

4
More Related Reports

•   VEGF Inhibition Therapy-Indicating and
  Prognostic Biomarkers, 2011
•   Biomarkers in Alzheimers Disease, 2011
•   Alzheimers Disease Autoantibodies, Vaccines
  and Therapeutic Antibodies Pipeline, 2011
•   Prostate Cancer Vaccines and Therapeutic
  Antibodies Pipeline, 2011
•   Breast Cancer Vaccines and Therapeutic
  Antibodies Pipeline, 2011
•   Alzheimers Disease Biomarkers in Cerebrospinal
  Fluid and Blood, 2011
•   Image-Based Biomarkers in Alzheimers Disease,
  2011
•   Lung Cancer Vaccines and Therapeutic
  Antibodies Pipeline, Strategies and Clinical

5
For More details

• http//www.aarkstore.com/reports/VEGF-Inhibition-T
  herapy-Indicating-and-Prognostic-Biomarkers-2011-1
  54228.html
• Vina
• Aarkstore.com
• Mob.No.918149852585
• Email enquiry_at_aarkstore.com
• URL http//www.aarkstore.in/